These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37837549)

  • 21.
    Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
    J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GRN is a prognostic biomarker and correlated with immune infiltration in glioma: A study based on TCGA data.
    Xu SM; Xiao HY; Hu ZX; Zhong XF; Zeng YJ; Wu YX; Li D; Song T
    Front Oncol; 2023; 13():1162983. PubMed ID: 37091137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Bioinformatic analysis of the clinical significance of calneuron 1 (CALN1) in glioma and its correlation with immune cell infiltration].
    Zhang H; Zhang J; Wang T
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Mar; 39(3):205-212. PubMed ID: 36946344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Matrix Remodeling-Associated Protein 8 as a Novel Indicator Contributing to Glioma Immune Response by Regulating Ferroptosis.
    Xu Z; Chen X; Song L; Yuan F; Yan Y
    Front Immunol; 2022; 13():834595. PubMed ID: 35281049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive Analysis of Prognostic and Immune Infiltrates for RAD51 in Human Breast Cancer.
    Li F; Zhang Y; Shi Y; Liu S
    Crit Rev Eukaryot Gene Expr; 2021; 31(4):71-79. PubMed ID: 34587437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma.
    Peng Y; Liu H; Wu Q; Wang L; Yu Y; Yin F; Feng C; Ren X; Liu T; Chen L; Zhu H
    BMC Cancer; 2023 Jun; 23(1):596. PubMed ID: 37380984
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Hu Z; Qu S
    Front Immunol; 2021; 12():683572. PubMed ID: 34267752
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Ge X; Xu M; Cheng T; Hu N; Sun P; Lu B; Wang Z; Li J
    Front Immunol; 2022; 13():974346. PubMed ID: 36275718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased ASF1B Expression Correlates With Poor Prognosis in Patients With Gliomas.
    Zhu H; Ouyang H; Pan X; Zhang Z; Tan J; Yu N; Li M; Zhao Y
    Front Oncol; 2022; 12():912101. PubMed ID: 35875094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.
    Zhang Z; Shen X; Tan Z; Mei Y; Lu T; Ji Y; Cheng S; Xu Y; Wang Z; Liu X; He W; Chen Z; Chen S; Lv Q
    Front Genet; 2022; 13():1053263. PubMed ID: 36712869
    [No Abstract]   [Full Text] [Related]  

  • 32. [Establishment of a prediction model for colorectal cancer immune cell infiltration based on the cancer genome atlas (TCGA) database].
    Ding TT; Zeng CX; Hu LN; Yu MH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):203-208. PubMed ID: 35435180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A gene expression-based study on immune cell subtypes and glioma prognosis.
    Zhong QY; Fan EX; Feng GY; Chen QY; Gou XX; Yue GJ; Zhang GH
    BMC Cancer; 2019 Nov; 19(1):1116. PubMed ID: 31729963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low expression of GRM4 is associated with poor prognosis and tumor immune infiltration in glioma.
    Fan H; Yan D; Fang X; Xiao L; Liang M; Wu H; Zhu G; Geng D; Liu Q
    Int J Neurosci; 2024 Dec; 134(12):1674-1686. PubMed ID: 38164693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Increased TRIM5 is associated with a poor prognosis and immune infiltration in glioma patients].
    Chen Y; Li Q; Zhang J; Gu R; Li K; Zhao G; Yuan H; Feng T; Ou D; Lin P
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2020 Jun; 37(3):469-479. PubMed ID: 32597089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and validation of a leukocyte-associated immunoglobulin-like receptor-1 prognostic signature for lower-grade gliomas.
    Fang Z; Lin L; Tu Z; Zhu X; Li J; Luo P; Huang K; Wu L
    Cancer Med; 2023 Jan; 12(1):712-732. PubMed ID: 35702880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
    Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
    Front Oncol; 2021; 11():611038. PubMed ID: 33937022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. M2 macrophage marker CHI3L2 could serve as a potential prognostic and immunological biomarker in glioma by integrated single-cell and bulk RNA-Seq analysis.
    Qian W; Wang Q; Zhang C; Zhu J; Zhang Q; Luo C
    J Gene Med; 2023 Sep; 25(9):e3523. PubMed ID: 37147894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
    Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
    Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
    Liu J; Xu K; Ma L; Wang Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.